Biomarker-Based Treatment Response After Switching From Benralizumab to Tezepelumab in Refractory Allergic Bronchopulmonary Mycosis.

IF 6.6 3区医学 Q1 ALLERGY

Journal of Investigational Allergology and Clinical Immunology Pub Date : 2026-07-29 Epub Date: 2026-04-13 DOI:10.18176/jiaci.1174

Yasuhito Suzuki, Junpei Saito, Mami Rikimaru, Ryuki Yamada, Tetsuya Egawa, Takahiro Kumanaka, Ryutaro Tanaka, Kentaro Kazama, Koshi Saito, Rina Harigane, Riko Sato, Hikaru Tomita, Natsumi Watanabe, Takashi Umeda, Ryuichi Togawa, Yuki Sato, Xintao Wang, Kenya Kanazawa, Yoshinori Tanino, Yoko Shibata

引用次数: 0

查看原文本刊更多论文

难治性过敏性支气管肺真菌病从贝那利珠单抗切换到Tezepelumab后基于生物标志物的治疗反应

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Investigational Allergology and Clinical Immunology 医学-过敏

CiteScore

7.10

自引率

9.70%

发文量

135

审稿时长

6-12 weeks

期刊介绍： The Journal of Investigational Allergology and Clinical Immunology (J Investig Allergol Clin Immunol) provides an attractive and very active forum for basic and clinical research in allergology and clinical immunology.Journal of Investigational Allergology and Clinical Immunology publishes original works, reviews, short communications and opinions.